SEARCH RESULTS

TAMI Industries’ ceramic membranes are renowned in the field of membrane separation processes for their durability and extreme efficiency

Purva Marwaha - 03-juil.-2017 08:07:47
      TAMI Industries’ ceramic membranes are renowned in the field of membrane separation processes for their durability and extreme efficiency   Specially adapted for the food processing, pharmaceutical and biotechnological industries.       The use of ceramic membranes has increased in popularity over recent years in the various industrial separation processes currently available on the market. Their characteristics of high mechanical resistance, durability and ease of use have contributed significantly to this increased popularity.       Although representing only 10% of the global market, in very many applications ceramic membranes are challenging organic membranes. The main advantages they offer being greater durability, significant chemical stability, complete temperature independence and improved mechanical resistance to pressure. Thus, corrosive products, steam sterilization, high-temperature separations or hydraulic accidents in circulation pumps are easy to control using ceramic membranes.       TAMI Industries’ R&D department has gone to considerable lengths to develop new inorganic membranes. This hard work has resulted in the creation of high-tech ceramic membranes with the exclusive characteristics of non-circular petal-shaped channels. Compared to circular channels, non-circular channels provide a larger filtration surface for the same external volume of the membrane thus ensuring improved filtration performance as well as increased turbulence and reduced fouling.       The original shapes of the ceramic membranes designed by TAMI Industries means they are more compact (patents on non-circular channels), which increases permeability and offers a wide choice of cut-off thresholds - Microfiltration, Ultrafiltration and Fine Ultrafiltration (patents on the layers), high mechanical resistance (patent on the base materials), significant chemical stability (pH range from 0 to 14), high heat resistance (up to 300 °C ), low risk of fouling, reliability and durability (an average useful life 3 to 4 times longer than their organic competitors).       The external dimensions of TAMI Industries’ ceramic membranes are compatible with all existing equipment and facilities on the market that use ceramic membranes. This functionality means that renovating industrial infrastructures is simple, only the ceramic membranes need to be replaced (process known as RETROFIT).       As a result of this R&D investment it is now possible to offer membranes with the best filtration surface /external volume ratio of the membrane associated with control over the shaping of the membrane’s materials, thus allowing very narrow distributions of the pore diameters and a more uniform performance. In addition, investments in external growth have guaranteed the manufacture of the supports, which means that TAMI Industries has complete control of the ceramic membrane production process from start to finish.       This investment has led to a significant improvement in performance and, therefore, increased energy savings, along with lower operating and infrastructure maintenance costs.       There are two separate ranges of ceramic membranes available:-   - A range of tubular shaped products for industry (Inside CéRAM)   - A range of flat products for frontal and cross-flow filtration for laboratory tests (Inside KéRAM).       Currently, TAMI Industries is the only company in the world capable of producing and offering such high-performance tubular ceramic membranes on an industrial scale.       Main fields of application:-   - pharmaceutical and biotechnological sectors - culture media clarification (production of amino acids, antibiotics, enzymes, vitamins, etc.)                   - food-processing sector – debacterization of milk, fractionation, standardization and concentration of milk and lactoserum (WPI/WPC), clarification of wines, fruit juices, cider and sweetened juices …                   - environmental sector – treatment of metallurgy effluents, oil/water separation (degreasing baths), laundry water, paper industries and textile industries effluent treatment…       This list is far from exhaustive, ceramic membranes can fulfill the requirements of numerous other applications.       The Indian Market has great potential for these ceramic membranes since all the sectors of application are recording double digit growth. Tami Industries has been present in India since the past 10 years and is supplying these membranes via partners. The French company is now looking to expand its operations in the Western & Southern regions of India and is therefore looking for partners who can import & distribute their products in India.       TAMI Industries, your ideal partner for all your filtration processes, is looking for partners to help with the commercial development of its products.       About TAMI Industries:   TAMI Industries, designs and manufactures industrial filters (ceramic membranes) for the separation of molecules or particles contained in liquids. It operates in the fields of Fine Ultrafiltration, Ultrafiltration and Microfiltration. TAMI offers a wide range of cut-off thresholds – microfiltration, ultrafiltration and fine ultrafiltration.   TAMI Industries , head office in Nyons (South-East France), is a global player in the ceramic membranes sector, 85% of its revenue being achieved internationally. Currently, TAMI Industries has four subsidiaries abroad, in Germany, Canada, Mexico and China.       For further information, please contact us or visit our website: www.tami-industries.com   About Business France:   Business France is the national agency supporting the international development of the French economy, responsible for fostering export growth by French businesses, as well as promoting and facilitating international investment in France. It promotes France’s companies, business image and nationwide attractiveness as an investment location, and runs the V.I.E international internship program. Business France has 1,500 personnel, both in France and in 70 countries throughout the world, who work with a network of public- and private-sector partners. For further information, please visit: www.businessfrance.fr and youbuyfrance.com.in .         Press contact:   Ms. Purva Marwaha   Business France, French Trade & Investment Commission in India   Trade Officer. Tel: 011 4319 6306 / @: purva.marwaha@businessfrance.fr       Company Contact:   Vincent GELEZEAU,   TAMI Industries, Area Manager   Tel.: + 33 (0)4 75 26 47 69   E-mail: vgelezeau@tami-industries.com  

TEKNIMED to launch new biomaterials & surgical solutions in orthopaedics and spine surgery in India

Thomas ILHE - 11-févr.-2016 08:39:46
  TEKNIMED to launch new biomaterials & surgical solutions in orthopaedics and spine surgery in India Medical Fair India – Mumbai, March 11-13 – Booth H60 TEKNIMED , designer, developer and manufacturer of innovative surgical products, will showcase its latest innovations for the Indian market at Medical Fair India 2016. The company recently registered a list of products 100% made in France some which are now available or will be available soon in India. TEKNIMED will first present its OPACITY+ product, low viscosity bone cement dedicated to vertebroplasty and kyphoplasty surgeries for spine application. The product has already been certified for the Indian market and is available. Three other products ( CEMFIX 1/3 , GENTAFIX 1/3/3MV and EUROSCREW PLA and PLA/TLP ) are being tested to receive certifications as per Indian regulations and will be available in India in April this year. CEMFIX and GENTAFIX are PMMA cement (respectively with and without antibiotics) with low, medium and standard viscosity dedicated to any knee, shoulder or hip prosthesis surgeries. EUROSCREW PLA and PLA/TCP resorbable interference screws are dedicated to Ligamentoplasty surgeries. TEKNIMED has strong expectations from the Indian market, as said by Ms. Isabelle Iversenc, APAC and MEA Export Manager: “ India is a highly dynamic market and the key words to enter this market are Innovation, quality and well-priced products. With our arthroplasty and vertebroplasty range of products, we have the solutions to meet the requirements of the Indian healthcare sector for innovative surgical and biomaterial products at an affordable price ”. To find out more about TEKNIMED and its products in India, please visit the company at Medical Fair India (11-13 March), Mumbai, at booth H60! About TEKNIMED: Started in 1990, TEKNIMED, world leader in biomaterial and at the forefront in medical solutions of the future, is present in various countries through a network of 250 distributors across the world. The company already manufactured for large global groups ref Depuy, Alphatec, Medtronic, Zimmer, Cook and offers the guarantee of high quality products recognised throughout the world. TEKNIMED R&D Team is very active and keeps working on new biomaterials or custom made projects for specific customers, such as orthopaedic, spinal, CMF or dental companies and has developed multiple partnerships with hospitals, universities and research centres worldwide. TEKNIMED is pleased to propose high quality and innovative French products on the basis of a strong and reliable quality system. About Business France: Business France is the national agency supporting the international development of the French economy, responsible for fostering export growth by French businesses, as well as promoting and facilitating international investment in France. It promotes France’s companies, business image and nationwide attractiveness as an investment location, and also runs the V.I.E international internship program. Business France has 1,500 personnel, both in France and in 70 countries throughout the world, who work with a network of public- and private-sector partners. For further information, please visit: www.businessfrance.fr and youbuyfrance.com.in .      Company contacts Ms. Isabelle IVERSENC TEKNIMED Asia, Middle East, USA Export Manager Tel: (+33) 5 34 25 27 38 @: i.iversenc@teknimed.com Press contacts: Ms. Purva MARWAHA Business France, French Trade Commission in India Trade Officer Tel : 011 4319 6306 @: purva.marwaha@businessfrance.fr

World HAI Forum: Global Call to Action to Fight

Julien Compain - 12-août-2011 12:15:28
                                            World HAI Forum: Global Call to Action to Fight                                              Antibiotic Resistance Over 70 international experts in medicine, infectious diseases, microbiology and epidemiology, from every continent, gathered at the Fondation Mérieux’s Conference Center for the third edition of the World HAI Forum on healthcare-associated infections, a bioMérieux initiative. Forum participants call upon national and international health authorities and policy makers, the medical and veterinary communities, Industry, and the general public to take action to avoid an impending public health catastrophe caused by the emergence and spread of bacteria that are resistant to all antibiotics. While research to discover novel antibiotics has slowed to a virtual standstill, bacterial resistance has increased due to the massive use and misuse of antibiotics, not only for human health, but also for animals. The treatment of certain common infections is becoming difficult and the success of immunosuppressive therapies and surgical interventions (organ transplants, cardiac surgery), which are associated with a high risk of bacterial infection, could be compromised. To the Forum experts, the emergence of pan-resistant NDM-1 bacteria and epidemic of multidrug-resistant E. coli infections currently in Europe should be taken as a major public health warning, indicating that a new era of antimicrobial resistance has begun. This must lead to a global awakening: the protection of antibiotics has now entered the sphere of sustainable development. In a continuation of calls to action and proposals made by major national and international organizations (WHO, ECDC, IDSA, CDC, etc.), the Forum’s participants identified priority action areas to fight bacterial resistance and recommended 12 very concrete actions to be implemented, in the short to mid-term, to effectively address this serious problem. Priority actions for policy makers and health authorities -          For animals, stop the administration of antibiotics used in human medicine and limit antibiotics to therapeutic use only. It is imperative to reserve the most important classes of antibiotics for humans. -          Banish, in all countries, the use of antibiotics as growth promoters in animal feed. -       Regulate the sale of antibiotics for use in human medicine and prohibit over-the-counter sales worldwide. -       Have international organizations (WHO, European Union) develop a charter on good antibiotic stewardship and have all the ministries of health worldwide sign it and commit to respecting it.  Priority actions for the human and veterinary healthcare communities -       Establish standardized, universal surveillance of antibiotic use and resistance and monitor the emergence and spread of new forms of bacterial resistance. -       Include, in the medical and veterinary school curricula, a solid training in bacterial resistance and the prudent use of antibiotics and establish on-the-job training programs for healthcare workers, taking into account the cultural specificities of each country. Priority actions for the general public -       Develop culturally sensitive awareness campaigns, targeted to the general public, explaining the importance of protecting antibiotics and using them only when absolutely necessary. -       Provide education about fundamental hygiene, such as handwashing to prevent the spread of infection. It is imperative to improve sanitation systems to eliminate resistant bacteria in wastewater. -       Include consumers in the development and implementation of action plans. Priority actions for lndustry -       Develop Point-of-Care and rapid diagnostic tests, which can be used at the patient’s bedside or the doctor’s office, to guide the prescription of antibiotics and avoid their prescription for viral infections. -       Stimulate research and development of novel antibiotics. -       Find new economic models, which reconcile public health interests with Industry needs for profitability. About the World HAI Forum To hear what experts discussed at the Forum: www.hai-forum.com For more information visit: www.bioMerieux.com/hai-resistance   Organized from June 27-29, the 3rd edition of the World HAI Forum was characterized by the exceptional geographical diversity of its participants, coming from 33 countries.  While most meetings focus on scientific developments retrospectively in an academic format, the World HAI Forum, which is held every two years, gives participating experts a chance to do prospective analysis of subjects that are not usually discussed. More time is devoted to sharing best practices, successes and failures in the fight against multidrug-resistant bacteria, as a basis for building effective action plans. A world leader in microbiology and a pioneer in resistance detection and susceptibility testing, bioMérieux works closely with healthcare professionals in the three key areas of Infection Control: Prevention, Surveillance and Intervention. Diagnostic tests are paramount to success in the fight against infections with resistant bacteria. As part of its commitment to fight HAIs and microbial resistance, bioMérieux has also held HAI symposia around the world over the past 3 years, in countries including the United States, Belgium, the Netherlands, Portugal, Spain, China, Japan, Korea, Colombia and Saudi Arabia. In India, bioMerieux has held six sessions of the HAI Forum across the Country, under the leadership of Dr. Chand Wattal - a recognized expert - with the active participation of leading Clinicians and Microbiologists. During the discussion experts highlighted the three main threats to public health globally and in India: Gram-negative organisms, which are multi-drug resistant as there are not many antibiotics to treat these organisms, common bacteria,  like Escherichia coli: (E. coli) are now producing enzymes which make the bacteria capable of de-activating all but the antibiotics that specialists reserve as a last line of, defense. Healthcare workers themselves may be contributing to the spread of infections by failing to get flu vaccinations and, in some countries, coming to work when they are ill rather than taking sick leave. Stress was laid on the need to ensure a continuous monitoring of infection, exchange of information and the adoption of a well defined policy for the rational use of antibiotics. About bioMérieux Advancing Diagnostics to Improve Public Health A world leader in the field of in vitro diagnostics for over 45 years, bioMérieux is present in more than150 countries through 39 subsidiaries and a large network of distributors. In 2010, revenues reached €1.357 billion with 87% of sales outside of France. bioMérieux provides diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are used for diagnosing infectious diseases and providing high medical value results for cancer screening and monitoring and cardiovascular emergencies. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products. bioMérieux is listed on the NYSE Euronext Paris market (Symbol: BIM – ISIN: FR0010096479). Other information can be found at www.biomerieux.com . Contacts    Media Relations      bioMérieux - Koren Wolman-Tardy - Tel: + 33 4 78 87 20 08    media@biomerieux.com   Pure Communications - Kathryn Cook  - Tel: + 1 910-509-3976   kathryn@purecommunicationsinc.com   Image Sept  - Laurence Heilbronn - Tel: + 33 1 53 70 74 64  lheilbronn@image7.fr   French Trade Commission -  Press Information: Deepika PRAKASH Press Officer French Trade Commission Embassy of France 2/50 E Shantipath, Chanakyapuri New Delhi 110021 Telephone: +91 11 43 19 63 51 Email: deepika.prakash@ubifrance.fr                                                                               
About
Sophie Clavelier, Country Head   Welcome to the French Trade Commission Business France in India!     Our key mission is to promote trade relations between France and India. We assist French- based companies seeking potential partners and new markets in India, while helping Indian businesses to identify potential French suppliers, commercial and technical partners.   In India, our 4 offices are located in business hubs, New Delhi, Mumbai, Bengaluru and Chennai. We have a dedicated multicultural team of 38 experts in the following growing sectors: Agrofood Industry Industry and Cleantech Lifestyle and Healthcare Tech & Services Our Trade Commission also has a Press office in charge of helping French companies to communicate in India as well as a Market Access Department enabling them to better understand and adjust to the Indian regulatory and fiscal framework. In

READ MORE

    
    You Buy France 

    

    Vivapolis  

   

    Healthindustry

   

    Axema

Facebook
Press area & Media Gallery
List of last comments